$144.53
20.64%
Nasdaq, Nov 19, 03:59 pm EST. Closed.
ISIN
US4576693075
Symbol
INSM

Insmed Incorporated Stock price

$144.46
+49.17 51.60% 1M
+37.05 34.49% 6M
-29.58 17.00% YTD
-59.10 29.03% 1Y
+119.84 486.76% 3Y
+114.00 374.26% 5Y
+129.84 888.10% 10Y
+129.56 869.53% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
+24.66 20.58%
ISIN
US4576693075
Symbol
INSM
Industry

Create a Free Account to create an Insmed Incorporated alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Key metrics

Basic
Market capitalization
$26.3b
Enterprise Value
$25.9b
Net debt
positive
Cash
$1.1b
Shares outstanding
219.3m
Valuation
P/E
negative
P/S | estimate
17.3 | 14.0
EV/Sales | estimate
17.0 | 13.8
EV/FCF | ex SBC
negative | negative
P/B
36.2
Financial Health
Equity Ratio
32.6%
Return on Equity
-172.8%
ROCE
-34.6%
ROIC
-66.4%
Debt/Equity
1.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$167.3m | 11.0%
SBC as % of FCF
-
SBC Growth 1Y
19.3%
Share Count Growth 1Y
3.2%
Shareholder Yield
-3.2%
Financials
Revenue | estimate
$1.5b | $1.9b
EBITDA
$-552.8m
EBIT
$-564.0m
Net Income
$-605.6m
Free Cash Flow | ex SBC
$-627.6m | $-794.8m
Growth
Revenue | estimate
240.0% | 208.7%
EBITDA
43.9%
EBIT
43.0%
Net Income
48.8%
Free Cash Flow
30.7%
Margin
Gross
84.4%
EBITDA
-36.4%
EBIT
-37.1%
Net
-39.9%
Free Cash Flow | ex SBC
-41.3% | -52.3%
More
EPS
$-2.8
FCF per Share
$-2.9
Short interest
7.2%
Employees
2k
Rev per Employee
$360.0k

Insmed Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Insmed Incorporated forecast:

29x Buy
94%
2x Hold
6%

Analyst Opinions

31 Analysts have issued a Insmed Incorporated forecast:

Buy
94%
Hold
6%

Insmed Incorporated Events

Past Events
NOV
16
Jefferies Global Healthcare Conference 2026
4 days ago
OCT
29
Q3 2026 Earnings Call
22 days ago
SEP
14
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
SEP
9
12th Annual Cantor Fitzgerald Global Healthcare Conference
2 months ago
AUG
6
Q2 2026 Earnings Call
4 months ago
JUL
16
Special Call - Insmed Incorporated
4 months ago
JUN
9
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
MAY
20
RBC Capital Markets Global Healthcare Conference 2026
6 months ago
MAY
12
Bank of America Global Healthcare Conference 2026
6 months ago
MAY
7
Q1 2026 Earnings Call
7 months ago
MAR
23
Shareholder/Analyst Call - Insmed Incorporated
8 months ago
MAR
10
Leerink Global Healthcare Conference 2026
8 months ago
MAR
2
TD Cowen 46th Annual Health Care Conference
9 months ago
FEB
19
Q4 2025 Earnings Call
9 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago
DEC
2
Evercore 8th Annual Healthcare Conference
12 months ago
NOV
18
Jefferies London Healthcare Conference 2025
about one year ago
OCT
30
Q3 2025 Earnings Call
about one year ago

Financial data from Insmed Incorporated

Sep '26
+/-
%
1,520 1,520
240% 240%
100%
- Direct Costs 237 237
126% 126%
16%
1,283 1,283
275% 275%
84%
- Selling and Administrative Expenses 960 960
52% 52%
63%
- Research and Development Expense 944 944
36% 36%
62%
-553 -553
44% 44%
-36%
- Depreciation and Amortization 11 11
109% 109%
1%
EBIT (Operating Income) EBIT -564 -564
43% 43%
-37%
Net Profit -606 -606
49% 49%
-40%

In millions USD.

Don't miss a Thing! We will send you all news about Insmed Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Insmed Incorporated Stock News

Positive
Proactive Investors
●
about 3 hours ago
Insmed Incorporated (NASDAQ:INSM) shares surged on Thursday after reports that French pharmaceutical group Sanofi is considering an acquisition of the US biotechnology company, which has a market value of about $26.28 billion. On Thursday afternoon, Insmed was trading at $141.84, up $22.04, or 18.4%.
Positive
Barrons
●
about 10 hours ago
Insmed stock jumps following a report saying Sanofi is eyeing a takeover of the biopharma company.
More Insmed Incorporated News

Company Profile

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Mr. Lewis
Employees 1,664
Founded 1988
Website insmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today